REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,886.00
Bid: 1,858.00
Ask: 1,864.00
Change: 18.00 (0.96%)
Spread: 6.00 (0.323%)
Open: 1,814.00
High: 1,918.00
Low: 1,814.00
Prev. Close: 1,868.00
GNS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition and strategic partnership

23 Feb 2017 07:00

RNS Number : 6110X
Genus PLC
23 February 2017
 

 

 

 

For immediate release 23 February 2017

Genus plc

('Genus' or the 'Group')

 

Acquisition and Strategic Partnership

Genus acquires Hermitage's genetic assets and enters into a strategic partnership

 

Genus, a leading global animal genetics company, and Hermitage, one of the longest established pig breeding companies in Europe, are pleased to announce that they have signed an agreement to enter into a strategic partnership covering the supply of porcine genetics in several markets.

 

PIC, Genus's porcine division, will acquire the genetic rights and intellectual property of Hermitage. Hermitage will also become a strategic supply chain and distribution partner for PIC. In addition, PIC will acquire certain Hermitage customer relationships in various geographies including Russia, the US and several European countries. The transaction is subject to a number of closing conditions which are expected to be fulfilled by the end of March 2017.

 

The partnership combines PIC's genetics expertise and quality, and Hermitage's supply chain network and operational excellence. This combination will strengthen PIC's ability to deliver genetic improvement in Europe and provide customers of both PIC and Hermitage with access to top-tier genetics and optimal technical and health services.

 

Hermitage was established in 1958 in Ireland and is one of the longest established porcine breeding and genetics companies in Europe. Over the years, Hermitage has grown into a multinational porcine breeding company serving pig producers in Europe and other international markets with high-health breeding stock. Hermitage's infrastructure includes nucleus farms and boar studs in Ireland and across Europe, as well as multiplication partners in key international territories.

 

Commenting on the transaction, Karim Bitar, Chief Executive of Genus, commented:

 

"The partnership with Hermitage is an ideal fit with our porcine strategy. It will provide Genus with the opportunity to accelerate genetic improvement by combining the PIC and Hermitage gene pools. In addition, Hermitage's strong supply chain and customer-service oriented team will strengthen our ability to serve pig producers efficiently and reliably."

 

Ned Nolan, owner of Hermitage, added:

 

"This is an exciting step for Hermitage, as we join forces with a global pioneer in our field. Our partnership with PIC will allow the continued use of the Hermitage gene pool to provide enhanced genetics to our global customer base. Hermitage shares PIC's values of pioneering genetic improvement for customers and we look forward to collaborating with PIC's team."

 

For further information, please contact:

 

Genus Tel: +44(0)1256 345970

Karim Bitar, Chief Executive

Stephen Wilson, Group Finance Director

Buchanan Tel: +44(0)207 466 5000

Charles Ryland /Vicky Hayns

 

This announcement is available on the Genus website www.genusplc.com

 

About Genus

Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across all livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

 

Genus's worldwide sales are made in seventy countries under the trademarks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chain.

 

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

 

With headquarters in Basingstoke, United Kingdom, Genus companies operate in thirty countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

 

About Hermitage

Hermitage was established in 1958 by the Nolan Family. Pedigree Landrace and Large White lines were purchased internationally and developed and selected with the support of Irish Government Central Test Stations in the 60s, 70s and 80s. Over the last 30 years Hermitage Genetics has expanded its Landrace, Large White, Duroc, Pietrain and Maxgro lines, becoming a pig breeding company dedicated to efficient and profitable pig production worldwide. Hermitage top class production facilities support customers across Europe, North America and Asia.

 

Hermitage has developed a science-based breeding program that drives genetic progress focused on traits that are of economic importance to the pig producer. Hermitage now tests over 30,000 pigs per year for lean efficient growth and collects data from more than 22,000 pure-bred sows at the genetic nucleus level. This data is analysed by Hermitage's proprietary BreedDirect BLUP software program and offered by Hermitage to customers through an online data portal. Hermitage Group was advised on the transaction by Investec Corporate Finance in Dublin.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQOKBDDDBKBABB
Date   Source Headline
3rd Feb 202010:51 amRNSBlock listing Interim Review
23rd Jan 20203:52 pmRNSNotification of Major Holdings
2nd Jan 202010:02 amRNSTotal Voting Rights
12th Dec 20192:17 pmRNSNOTIFICATION OF MAJOR HOLDINGS
2nd Dec 20194:45 pmRNSTotal Voting Rights
20th Nov 20197:00 amRNSAppointment of Chief Financial Officer
15th Nov 20196:18 pmRNSDirector/PDMR Shareholding
14th Nov 20191:23 pmRNSResult of AGM
14th Nov 20197:00 amRNSAGM TRADING UPDATE
1st Nov 201912:05 pmRNSTotal Voting Rights
14th Oct 20198:00 amRNSAnnual Report and Annual General Meeting
10th Oct 20193:30 pmRNSDirector/PDMR Shareholding
3rd Oct 20193:06 pmRNSNOTIFICATION OF MAJOR HOLDINGS
2nd Oct 20193:38 pmRNSNotification of Major Holdings
1st Oct 20195:23 pmRNSTotal Voting Rights
20th Sep 201912:38 pmRNSDirector/PDMR Shareholding
18th Sep 20196:09 pmRNSDirector/PDMR Shareholding
17th Sep 20191:24 pmRNSDirector/PDMR Shareholding
12th Sep 20192:59 pmRNSDirector/PDMR Shareholding
11th Sep 20198:02 amRNSCORRECTION: Outcome of IntelliGen Litigation
11th Sep 20197:00 amRNSOutcome of latest IntelliGen Litigation
10th Sep 20197:00 amRNSOUTCOME IN LATEST INTELLIGEN LITIGATION
5th Sep 20197:00 amRNSPreliminary Results
22nd Aug 20197:00 amRNSAppointment of Chief Executive Officer
1st Aug 20195:49 pmRNSBlock listing Interim Review
1st Aug 20195:46 pmRNSTotal Voting Rights
30th Jul 201912:12 pmRNSNOTIFICATION OF MAJOR HOLDINGS
9th Jul 20195:12 pmRNSNotification of Major Holdings
3rd Jul 20197:00 amRNSNotification of Major Holdings
1st Jul 20191:45 pmRNSTotal Voting Rights
18th Jun 20193:29 pmRNSNotification of Major Holdings
3rd Jun 20195:43 pmRNSTotal Voting Rights
24th May 20196:03 pmRNSDirector/PDMR Shareholding
16th May 20199:58 amRNSStrategic porcine collaboration in China
1st Apr 20191:54 pmRNSTotal Voting Rights
25th Mar 20197:00 amRNSGenus Chief Executive Transition
4th Mar 20193:11 pmRNSDirector/PDMR Shareholding
1st Mar 20192:00 pmRNSTotal Voting Rights
28th Feb 20197:00 amRNSInterim Results
1st Feb 20192:00 pmRNSBlock listing Interim Review
2nd Jan 20192:49 pmRNSTotal Voting Rights
11th Dec 20181:37 pmRNSDirector/PDMR Shareholding
7th Dec 20187:00 amRNSResult of placing to raise approximately £68m
6th Dec 20184:41 pmRNSProposed placing to raise approximately £68m
21st Nov 201812:00 pmRNSDirector Declaration
15th Nov 20184:00 pmRNSResult of AGM
15th Nov 20187:00 amRNSAGM Trading Update
1st Nov 20182:00 pmRNSTotal Voting Rights
12th Oct 20184:53 pmRNSAnnual Report and Annual General Meeting
12th Oct 20184:37 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.